Cadrenal Therapeutics, Inc.
CVKD- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001937993
No open-market purchases or sales by Cadrenal Therapeutics, Inc. insiders were filed in the last 90 days; 19 institutions reported holding it in 13F filings for Q2 2026, worth $379.6K in total; no superinvestor holds it.
13F holders, Q1 2026
Institutional positions in Cadrenal Therapeutics, Inc. as of Mar 31, 2026. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 20
- +1 vs. Q4 2025
- Shares held
- 91.1K
- +23.5K (+34.7%) vs. Q4 2025
- Total value
- $460.1K
- +$1.75K (+0.4%) vs. Q4 2025
- New holders
- 5
- 2 more added
- Sold out
- 4
- 5 more reduced
1 institution that held it in Q4 2025 haven't filed for Q1 2026 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q4 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CVKD on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 19 | $379.6K |
| Q1 2026 | 20 | $460.1K |
| Q4 2025 | 20 | $823.9K |
| Q3 2025 | 20 | $1.57M |
| Q2 2025 | 17 | $823.9K |
| Q1 2025 | 16 | $1.22M |
| Q4 2024 | 10 | $215.5K |
| Q3 2024 | 2 | $68 |
| Q2 2024 | 9 | $165.0K |
| Q1 2024 | 10 | $1.04M |
| Q4 2023 | 6 | $407.5K |
| Q3 2023 | 9 | $751.9K |
| Q2 2023 | 3 | $429 |
| Q1 2023 | 3 | $1.34K |
| Q4 2022 | 0 | $0 |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q1 2026
Shares, value and share of portfolio for each institution holding Cadrenal Therapeutics, Inc.; share changes are against Q4 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Curio Wealth, LLC | 1 | $5 | 0.00% | 00.0% | Unchanged |
| Citigroup Inc | 1 | $5 | 0.00% | +1 | New |
| UBS Group AG | 3 | $15 | 0.00% | −1,041−99.7% | Reduced |
| Caldwell Sutter Capital, Inc. | 5 | $26 | 0.00% | 00.0% | Unchanged |
| Farther Finance Advisors, LLC | 25 | $123 | 0.00% | 00.0% | Unchanged |
| IFP Advisors, Inc | 30 | $154 | 0.00% | 00.0% | Unchanged |
| Archer Investment Corp | 35 | $179 | 0.00% | 00.0% | Unchanged |
| Wells Fargo & Company | 99 | $507 | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 100 | $512 | 0.00% | −980−90.7% | Reduced |
| Harbour Investments, Inc. | 100 | $512 | 0.00% | 00.0% | Unchanged |
| Rockefeller Capital Management L.P. | 150 | $768 | 0.00% | −150−50.0% | Reduced |
| RWM Asset Management, LLC | 200 | $1.02K | 0.00% | +200 | New |
| Advisor Group Holdings, Inc. | 300 | $1.54K | 0.00% | −200−40.0% | Reduced |
| Tower Research Capital LLC (TRC) | 393 | $2.01K | 0.00% | −139−26.1% | Reduced |
| Cygnus Capital Advisors, LLC | 1,492 | $8.00K | 0.01% | +1,492 | New |
| BlackRock, Inc. | 5,496 | $28.1K | 0.00% | +1,974+56.0% | Added |
| JPMorgan Chase & Co | 7,500 | $31.9K | 0.00% | 00.0% | Unchanged |
| Vanguard Fiduciary Trust Co | 8,311 | $42.6K | 0.00% | +8,311 | New |
| Geode Capital Management, LLC | 21,626 | $110.7K | 0.00% | +7,098+48.9% | Added |
| Vanguard Capital Management LLC | 45,201 | $231.4K | 0.00% | +45,201 | New |
| DRW Securities, LLC | 0 | $0 | 0.00% | −25,152−100.0% | Sold out |
| LPL Financial LLC | 0 | $0 | 0.00% | −13,000−100.0% | Sold out |
| Clearstead Advisors, LLC | 0 | $0 | 0.00% | −150−100.0% | Sold out |
| Bank of America Corp | 0 | $0 | 0.00% | −1−100.0% | Sold out |
| Vanguard Group Inc | – | – | – | – | Not filed |